During the corresponding time, Newamsterdam Pharma Company N V recorded a revenue increase by 2.08 % year on year, sequentially revenue grew by 9400 %. While revenue at the Newamsterdam Pharma Company N V 's corporate clients
Newamsterdam Pharma N V's Comment on Sales, Marketing and Customers
The Federal Food, Drug, and Cosmetic Act (FDCA) and the Orphan Drug Act establish regulatory exclusivity provisions that influence the marketing and approval of pharmaceutical drugs. These provisions include exclusivity periods for new chemical entities (NCEs), previously approved active moieties, orphan drugs intended to treat rare diseases affecting fewer than 200,000 individuals in the United States, and pediatric exclusivity granted for specific pediatric studies. Such exclusivity periods restrict the submission and approval of abbreviated new drug applications (ANDAs) and 505(b)(2) new drug applications (NDAs), thereby limiting competition for designated timeframes. The affected market segments include drugs for rare diseases or conditions impacting fewer than 200,000 people in the U.S. and pediatric populations requiring targeted studies to obtain exclusivity.
News about Newamsterdam Pharma Company N v Contracts
NewAmsterdam Pharma Presents Additional Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia at AHA Scientific Sessions 2024 At the American Heart Association (AHA) Scientific Sessions 2024, NewAmsterdam Pharma presented compelling new data from its pivotal Phase 3 BROOKLYN clinical trial, which evaluated the efficacy and safety of Obicetrapib in patients with heterozygous familial hypercholesterolemia (HeFH). The trial results indicate that Obicetrapib has met its primary endpoint, demonstrating a mean reduction in low-density lipoprotein cholesterol (LDL-C) of 36.3% at day 84 and an impressive 41.5% at day 365, compared to a pl...
: NewAmsterdam Pharma is set to announce topline data from its pivotal Phase 3 BROOKLYN clinical trial evaluating obicetrapib in patients with heterozygous familial hypercholesterolemia (HeFH) on July 29, 2024. This announcement is anticipated to contribute significant insights into the efficacy and safety of obicetrapib, a novel therapeutic agent targeting lipid regulation. Heterozygous familial hypercholesterolemia is a genetic condition characterized by elevated levels of low-density lipoprotein cholesterol (LDL-C), leading to an increased risk of cardiovascular disease. Management of HeFH typically involves lifestyle modifications and lipid-lowering therapies, including statins and PCSK9 inhibitors. How...
NewAmsterdam Pharma, a pioneering pharmaceutical company, has successfully enrolled over 9,000 patients in the highly anticipated Phase 3 PREVAIL Global Cardiovascular Outcome Trial. This pivotal study aims to evaluate the potentially groundbreaking effect of Obicetrapib in patients with established atherosclerotic cardiovascular disease (ASCVD). Due to the overwhelming interest from both patients and medical institutions, the enrollment period has been extended until the end of April.The PREVAIL trial represents a significant milestone in the fight against cardiovascular disease, a leading cause of morbidity and mortality worldwide. Obicetrapib, a novel therapeutic targeting lipid metabolism, shows great pr...
Newamsterdam Pharma N V’s Comment on Sales, Marketing and Customers
The Federal Food, Drug, and Cosmetic Act (FDCA) and the Orphan Drug Act establish regulatory exclusivity provisions that influence the marketing and approval of pharmaceutical drugs. These provisions include exclusivity periods for new chemical entities (NCEs), previously approved active moieties, orphan drugs intended to treat rare diseases affecting fewer than 200,000 individuals in the United States, and pediatric exclusivity granted for specific pediatric studies. Such exclusivity periods restrict the submission and approval of abbreviated new drug applications (ANDAs) and 505(b)(2) new drug applications (NDAs), thereby limiting competition for designated timeframes. The affected market segments include drugs for rare diseases or conditions impacting fewer than 200,000 people in the U.S. and pediatric populations requiring targeted studies to obtain exclusivity.
Sources:
Newamsterdam Pharma Company N v’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Newamsterdam Pharma Company N v’s corporate clients.
For your research, we’ve provided 9 tables on Newamsterdam Pharma Company N v corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
